Cannabis and Pregnancy: Risks and Evidence

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

Using cannabis during pregnancy is associated with measurable risks to the fetus and newborn — most consistently, lower birth weight Strong evidence^[1][2]. Other potential risks (preterm birth, stillbirth, behavioral or cognitive effects in childhood) show up in some studies but not others, and the research is complicated by co-use of tobacco, socioeconomic stress, and other unmeasured factors Weak / limited Disputed.

No trimester, no dose, and no route of administration (smoking, vaping, edibles, CBD-only products) has been shown to be safe in pregnancy No data. Major medical organizations — the American College of Obstetricians and Gynecologists (ACOG), the U.S. Surgeon General, and the World Health Organization — all recommend against cannabis use during pregnancy and breastfeeding ^[1][2][3].

This is not medical advice. If you are pregnant, trying to conceive, or breastfeeding, talk to a clinician. Honest disclosure to your OB or midwife will get you better care, not legal trouble in most jurisdictions—but the legal landscape varies, so know your local rules.

What the evidence shows: established and probable risks

Lower birth weight (most replicated finding). Infants exposed to cannabis prenatally weigh roughly 100–150 grams less on average than unexposed infants, even after adjusting for tobacco use Strong evidence^[1][2]. A 2016 meta-analysis in BMJ Open pooled 24 studies and found consistent associations with reduced birth weight and increased NICU admission ^[1]. A 2022 systematic review and meta-analysis in JAMA Network Open reached the same conclusion across multiple cohorts ^[2].

Preterm birth. Multiple cohort studies report a modest increase in preterm delivery (before 37 weeks) among people who use cannabis during pregnancy Weak / limited^[1][2]. Effect sizes are smaller and less consistent than the birth-weight signal. Disentangling cannabis from tobacco co-use remains difficult, and confounding by other factors (stress, poverty, healthcare access) is hard to fully eliminate.

Stillbirth. The Stillbirth Collaborative Research Network, an NIH-funded multi-site study, found associations between cannabinoid exposure and stillbirth, but could not separate cannabis from tobacco use; the evidence remains weak Weak / limited^[4].

Biological mechanism. THC crosses the placenta and reaches fetal tissues Strong evidence^[5]. The endocannabinoid system (CB1 and CB2 receptors and their ligands) plays a documented role in placental function, implantation, fetal brain development, and neural cell proliferation Strong evidence^[6]. This provides plausible biological basis for harm even if epidemiological signals are modest.

What might be risky: weaker or conflicting evidence

Neurodevelopmental and behavioral effects in childhood. Long-running prospective cohort studies (the Ottawa Prenatal Prospective Study and the Maternal Health Practices and Child Development Study) reported associations between prenatal cannabis exposure and later deficits in attention, impulse control, and executive function Weak / limited^[7]. More recent analyses from the large ABCD study found small associations between prenatal cannabis exposure and psychopathology symptoms in children ages 10–12 Weak / limited. However, these studies cannot prove causation—families that use cannabis during pregnancy also differ in parental education, parenting style, ongoing substance use, and other factors that independently affect child development. The causal attribution remains uncertain.

Pregnancy loss and congenital anomalies. Evidence is inconsistent and contradictory Disputed. Some epidemiological studies find small increases in specific anomalies (e.g., gastroschisis); others find no excess risk. Meta-analyses have reached different conclusions, and confounding by other drug use and maternal factors is difficult to exclude.

CBD-only products. Widely marketed as a 'safe' or 'non-intoxicating' alternative. There are essentially no controlled human pregnancy safety data for cannabidiol No data. Animal studies have shown reproductive and developmental toxicity at high doses. The FDA has explicitly warned against CBD use during pregnancy and breastfeeding ^[10].

Marketing claims without evidence

Cannabis for morning sickness or hyperemesis gravidarum. A 2018 study documented that when a pregnant 'mystery shopper' called U.S. cannabis dispensaries, a substantial proportion of staff recommended cannabis products for nausea Strong evidence^[11]. However, there are no randomized controlled trials showing that cannabis safely or effectively treats pregnancy-related nausea No data.

A documented complication exists on the flip side: cannabinoid hyperemesis syndrome (CHS)—a condition where chronic cannabis users develop severe, intractable cyclic vomiting Strong evidence^[12]. Some pregnant patients hospitalized for presumed hyperemesis gravidarum have actually had CHS, and their symptoms resolved only after stopping cannabis. Using cannabis to treat severe vomiting in pregnancy can paradoxically worsen or trigger this syndrome.

Standard treatments for morning sickness have far more safety data. First-line is vitamin B6 (pyridoxine) alone or combined with doxylamine (the active ingredient in Diclegis/Diclectin), supported by decades of pregnancy use and multiple randomized trials Strong evidence^[13]. Second-line options (ondansetron, metoclopramide, promethazine) are well-characterized in pregnancy and can be discussed with your clinician.

'Natural' is not a safety claim. Cannabis is a botanical, but 'natural' does not mean safe in pregnancy—it is a marketing category, not evidence of safety.

Comparison with standard treatments

For the conditions most commonly cited as reasons to use cannabis during pregnancy:

Nausea, vomiting, and hyperemesis gravidarum:

• First-line: vitamin B6 (pyridoxine) ± doxylamine (Diclegis/Diclectin), with decades of pregnancy safety data and randomized trial support Strong evidence^[13].
• Second-line: ondansetron, metoclopramide, promethazine, with established safety profiles in pregnancy.
• Cannabis: no controlled-trial evidence in pregnant patients; documented risk of worsening cannabinoid hyperemesis syndrome No data^[12].

Anxiety and insomnia:

• First-line: cognitive behavioral therapy (CBT), sleep hygiene, and psychosocial support.
• Medication: pregnancy-considered SSRIs (e.g., sertraline) have decades of observational and trial data supporting relative safety Strong evidence.
• Cannabis: no controlled-trial evidence in pregnant patients; teratologic risk is not well-characterized No data.

Pain (chronic, musculoskeletal, or other):

• First-line: physical therapy, non-pharmacological approaches, acetaminophen.
• Medication: NSAIDs are generally avoided in the third trimester; opioids are used when necessary but carry their own risks.
• Cannabis: no controlled-trial evidence in pregnant patients No data.

None of these standard treatments are risk-free. The comparison is not 'cannabis versus a highly toxic drug'—it is 'cannabis (poorly studied in pregnancy, signal of fetal growth restriction) versus medications with decades of pregnancy safety data or alternatives with better evidence.'

What we don't know

• Dose-response. We lack good data on whether occasional or low-dose use carries the same risk as daily or heavy use. Daily/heavy use shows stronger signals in cohort studies, but direct dose-response studies in pregnancy are absent.
• Route of administration. Smoking, vaping, edibles, and dabs likely have different pharmacokinetics and combustion byproduct exposure, but pregnancy studies rarely distinguish between routes.
• High-THC modern cannabis. Most longitudinal pregnancy studies were started in the 1980s–2000s, when average THC content was 3–8%. Today's flower often exceeds 15% THC, and concentrates reach 60–90%. The risk profile of modern high-potency cannabis in pregnancy is unknown.
• CBD specifically. Minimal human pregnancy data exist. No prospective cohort studies or trials have examined CBD-only exposure in pregnancy.
• Causation vs. correlation. Epidemiological studies have struggled to disentangle cannabis from tobacco, alcohol, polysubstance use, poverty, maternal stress, and parental education. Residual confounding likely remains in most observational studies Disputed.
• Long-term effects in older children and adolescence. Most neurodevelopmental studies follow children to age 10–14. Whether prenatal cannabis exposure increases risk for mental health or substance use problems in late adolescence and adulthood is not well-established.

Risks summary and clinical bottom line

Established or likely risks:

• Lower birth weight (100–150g reduction).
• Possibly higher rates of NICU admission and preterm birth (signals are weaker and harder to isolate from other factors).

Possible but uncertain risks:

• Stillbirth (weak evidence; confounding by tobacco not fully excluded).
• Neurodevelopmental or behavioral effects in childhood (weak evidence; correlation vs. causation unclear).
• Specific congenital anomalies (disputed; conflicting evidence across studies).
• Cannabinoid hyperemesis syndrome misdiagnosed as hyperemesis gravidarum.

Unknown:

• Safe dose or threshold.
• Safe trimester (animal data suggest early pregnancy and late pregnancy both expose the endocannabinoid system).
• Safety of CBD-only products (no human data).
• Long-term effects of high-potency modern cannabis in pregnancy.

Why medical organizations recommend against use: Given that (1) THC crosses the placenta, (2) the endocannabinoid system is involved in fetal development and placental function, (3) the most consistent epidemiological signal points to fetal growth restriction, and (4) effective alternatives with better safety data exist for the conditions people commonly cite—ACOG, the U.S. Surgeon General, and the WHO all recommend abstinence during pregnancy and breastfeeding.

Practical advice: If you are using cannabis and become pregnant, or are thinking about becoming pregnant, talk to your OB or midwife. Stopping abruptly is generally safe and will not harm a pregnancy; continuing use during pregnancy carries risks you cannot undo later. Honest disclosure to your clinician will not result in legal jeopardy in most jurisdictions—but legal status varies by location, so know your rights where you live.

This is not medical advice. This article summarizes publicly available evidence current to October 2026. Your situation is unique. Consult your healthcare provider.

Sources

How this page was made

Related

• Cannabis and Cognitive Decline — Evidence on cannabis, memory loss, and dementia risk in adults and older people.
• Cannabis and the Developing Brain — How THC and CBD interact with adolescent brain maturation, and what the evidence actually...
• Cannabis and Pregnancy Nausea — Nausea relief reported by pregnant users, but substantial fetal risks and no controlled tr...
• Risks of Cannabis Use in Adolescents — Evidence summary of cannabis-related harms during critical brain development years.